Sialyl Glycans and Siglecs in the Tumor Microenvironment: A Survey

www.surveyx.cn

Abstract

This survey paper provides a comprehensive analysis of the interactions between sialyl glycans and Siglecs within the tumor microenvironment (TME), emphasizing their critical roles in immune modulation and cancer progression. The paper is structured to explore the significance of these interactions, highlighting their implications for immune escape mechanisms that undermine the efficacy of cancer immunotherapies. It delves into the complex dynamics of the TME, examining the limitations of current immune checkpoint inhibitors and the challenges posed by glycan profiling and detection. The survey also discusses recent advancements in glycoimmunology, including innovative therapeutic strategies targeting Siglecs, the integration of nanomedicine for targeted drug delivery, and the development of personalized medicine approaches. The paper underscores the importance of understanding genetic variability and glycosylation patterns in influencing immune responses and treatment outcomes. Recent technological advancements in glycan analysis have enhanced the characterization of complex glycan structures, providing valuable insights into their roles in immune modulation and cancer therapy. The survey concludes by highlighting the need for continued research to develop targeted interventions that can effectively disrupt sialyl glycan-Siglec interactions, enhance antitumor immunity, and improve cancer treatment outcomes. By leveraging advancements in glycan analysis and personalized medicine, the ongoing evolution of these fields promises to transform cancer treatment and offer new hope for overcoming immune escape and resistance mechanisms.

1 Introduction

1.1 Structure of the Survey

This survey provides a comprehensive analysis of the roles of sialyl glycans and Sialic acid-binding immunoglobulin-like lectins (Siglecs) in the tumor microenvironment (TME), focusing on their mechanisms of action and implications for cancer immunotherapy. It emphasizes the intricate interactions between Siglecs and sialoglycans, which are prevalent on cell membranes and modulate immune responses, thereby facilitating tumor immune evasion [1, 2]. The introduction sets the context for understanding the significance of sialyl glycan-Siglec interactions in immune escape mechanisms.

Section 2 provides background and definitions, detailing key concepts such as sialyl glycans, Siglec proteins, the TME, immune escape, cancer immunotherapy, and glycoimmunology.

Section 3 explores the specific contributions of sialyl glycans and Siglecs to immune escape within the TME, subdivided to examine the significance of these interactions, the signaling pathways activated by Siglecs, and the effects of genetic variability and glycosylation patterns.

In Section 4, the challenges in cancer immunotherapy related to sialyl glycans and Siglecs are analyzed. This section addresses the limitations of current immune checkpoint inhibitors, particularly



Figure 1: chapter structure

their variable efficacy across cancer types, and the complexities of glycan profiling and detection, which are crucial for elucidating the immunosuppressive mechanisms employed by cancer cells and for advancing glycoimmunology as a therapeutic strategy [3, 4].

Section 5 highlights recent advancements in glycoimmunology, focusing on innovative therapeutic strategies, nanomedicine, and personalized medicine approaches. Notably, it discusses significant technological advancements in glycan analysis, including mass spectrometry and novel enzymatic methods, which improve the accuracy and efficiency of glycan characterization, facilitating deeper insights into their roles in biological processes and disease mechanisms [3, 5, 6, 7, 2].

The paper synthesizes key insights into sialyl glycans and Siglecs, underscoring their critical roles in immune modulation and cancer biology. Understanding these glycan structures and their interactions with Siglecs is vital for advancing cancer immunotherapy, as they are involved in tumor cell survival, drug resistance, and metastasis. The findings highlight the potential for targeting sialylated glycans and Siglecs in developing novel therapeutic strategies to enhance cancer treatment outcomes [8, 2, 6].The following sections are organized as shown in Figure 1.

2 Background and Definitions

2.1 Sialyl Glycans and Glycobiology

Sialyl glycans, characterized by sialic acid residues, play pivotal roles in cellular communication, immune response, and pathogen recognition. Their structural complexity arises from sialylation, where sialic acid is enzymatically added to glycan chains by sialyltransferases, essential for biosynthesis [2]. Positioned terminally, sialic acids impart a negative charge, influencing molecular interactions and signaling pathways [9]. The diversity of sialyl glycans, augmented by linkage isomers, contributes to N-glycans' structural variability and functional specificity, affecting immune recognition and pathogen binding [5].

In cancer, altered glycosylation, including sialylation, marks malignancy. Tumor-associated carbohydrate antigens (TACAs), like sialyl-Tn (STn), are overexpressed in cancer cells, serving as immunotherapy targets. These modifications promote tumor progression by mimicking host structures,

aiding immune evasion [7]. Host genetic variability also influences sialylated glycans' expression and function, impacting host-pathogen interactions and infection susceptibility, such as influenza A [10]. This variability underscores the complexity of glycan-mediated interactions in the immune landscape, particularly within the tumor microenvironment, where immune escape mechanisms are crucial for cancer cell survival.

2.2 Siglecs Proteins

Siglecs (Sialic acid-binding immunoglobulin-like lectins) are cell surface receptors on immune cells, modulating responses through interactions with sialyl glycans. Their affinity for sialic acid-containing glycans is vital for regulating immune homeostasis, enabling differentiation between self and non-self, and influencing inflammation resolution and tolerance [11, 12, 9, 5, 2]. Siglecs have distinct ligand specificities and expression patterns, contributing to diverse immune regulatory roles.

Siglecs are significant in various immune cells. For instance, Siglec-G is crucial for B-cell signaling and autoimmunity by binding to sialylated ligands [13]. It, along with CD22, modulates B-cell receptor signaling, influencing immune responses. Siglec-E regulates TLR4 signaling in macrophages, controlling inflammation [14]. In the tumor microenvironment, Siglecs interact with hypersialylated glycans on tumor cells, aiding immune evasion. Siglec-15's role in modulating immune responses highlights its potential as a cancer immunotherapy target [15]. The biochemical nature of Siglec ligands, including gangliosides, is crucial in mediating responses in immune and nervous systems [16].

The interplay between Siglecs and sialyl glycans, influenced by N-glycosylation, is critical for immunoglobulin functionality and immune system homeostasis [17]. This complex network presents opportunities for therapeutic interventions, such as Siglec-Fc fusion proteins targeting the sialic acid-Siglec axis in cancer treatment [18]. Understanding Siglecs' functions in modulating immune responses, particularly their interactions with sialylated glycans, is crucial for developing effective therapeutic strategies to address immune dysregulation in cancer and other diseases, informing targeted clinical interventions [1, 13, 12, 19].

2.3 Tumor Microenvironment (TME)

The tumor microenvironment (TME) is a complex ecosystem influencing cancer progression and treatment responses. It comprises diverse non-malignant cells, including immune, stromal, endothelial cells, and fibroblasts, interacting with cancer cells to create a supportive niche for tumor growth and metastasis. The TME modulates cancer cell behavior and facilitates immune escape mechanisms [20].

A critical TME aspect is the metabolic competition between tumor and immune cells, leading to an immunosuppressive environment hindering cancer therapies [21]. Cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), and tumor-associated neutrophils (TANs) contribute to this landscape, promoting tumor survival [22]. Targeting macrophages in the TME can enhance treatment effectiveness, underscoring their role in modulating the tumor milieu [23].

The TME's complexity influences tumors' immune composition, impacting prognosis and treatment outcomes [20]. Immune cells, including T cells, B cells, and macrophages, orchestrate immune escape stages regulated by cytokines like IFN, TNF, and IL-6, modulating PD-L1 expression and contributing to immune evasion [24]. Characterizing biologically distinct tumor regions' influence on immune cell distribution and behavior is essential [25].

Studies using synthetic multispecies data from agent-based TME models have predicted macrophage phenotypes and classified tumor behaviors, highlighting advanced modeling techniques' potential in understanding TME dynamics [26]. These insights are crucial for developing innovative therapeutic strategies to disrupt tumor-supportive interactions within the TME, enhancing cancer therapies' efficacy.

2.4 Immune Escape and Evasion Mechanisms

Tumors employ sophisticated strategies to evade immune detection, with sialyl glycans and Siglecs playing key roles. Sialyl glycans mimic host structures through terminal sialic acid residues, pre-

venting immune recognition and promoting evasion [12]. Sialyl linkage isomers' structural diversity complicates mimicry detection and characterization in complex samples [7].

A central mechanism involves exploiting immune checkpoint pathways, like PD-L1/PD-1, inhibiting T cell activation and promoting tolerance [4]. Siglecs, as sialic acid-binding receptors, modulate responses by interacting with sialylated ligands on tumor cells, inhibiting activation and fostering an immunosuppressive environment [13]. Carbohydrate sulfation influences Siglecs' binding affinity, adding complexity to evasion mechanisms [16].

Factors contributing to Siglec activation by tumor-associated sialoglycans impact antitumor immunity, presenting therapeutic challenges [14]. Tumor heterogeneity and TME interactions contribute to treatment resistance, complicating efforts to overcome immune escape [27]. This complexity is exemplified by low T-cell infiltration in solid tumors, limiting immunotherapies' effectiveness [21].

In cancers like acute myeloid leukemia (AML), immune escape mechanisms evolve due to genomic heterogeneity and immune interactions over time [28]. The balance between immunosurveillance and escape is critical, with cancer cells employing strategies to evade recognition and attack. Altered glycosylation in B cells and IgG can impair responses and contribute to autoimmune pathogenesis [17].

Glycan-binding proteins, particularly Siglec-8, modulate eosinophil functions, highlighting immune evasion mechanisms' complexity [12]. Challenges in binding to STn-expressing cells without affecting non-target tissues limit current methods' diagnostic and therapeutic potential [7]. The interplay between sialyl glycans and Siglecs within the TME is central to tumors' evasion mechanisms, highlighting the need for advanced analytical techniques and therapeutic strategies [29].

2.5 Cancer Immunotherapy and Immune Checkpoint Inhibitors (ICIs)

Cancer immunotherapy, a transformative oncology approach, harnesses the immune system to eradicate tumor cells. Immune checkpoint inhibitors (ICIs) block pathways restricting T-cell activation, enhancing anti-tumor responses [30]. ICIs target molecules like CTLA-4 and PD-1/PD-L1, maintaining homeostasis but exploited by tumors to evade surveillance.

Despite potential, ICIs' efficacy is limited, benefiting only a subset of patients [31]. This limited effectiveness arises from tumor heterogeneity, the immunosuppressive TME, and immune escape mechanisms [32]. A challenge is identifying biomarkers to predict responses and guide decisions, as current methods for evaluating TME changes are inadequate [33].

The TME often creates an immunosuppressive environment impairing responses. This results from upregulating immune checkpoints (ICs) and ligands, inhibiting T cell activation and promoting evasion. Combination therapies targeting inhibitory pathways and modulating the TME aim to enhance ICIs' potential and improve outcomes [34, 35]. Understanding evasion and resistance mechanisms is crucial for improving immunotherapy design, expanding ICIs' benefits to a broader population.

2.6 Glycoimmunology

Glycoimmunology, an emerging field, explores glycans' role in modulating immune responses, offering insights into cancer research and therapies. It investigates interactions between glycans, glycan-binding proteins like selectins and Siglecs, and the immune system, crucial in physiological and pathological contexts [6]. Targeting these interactions is promising for cancer immunotherapy.

Technological advancements have enabled comprehensive glycan analyses [3]. Innovations in experimental models and single-cell analysis facilitate studies of glycan-mediated modulation, offering research roadmaps [4]. Single-cell level interaction dissection is valuable for understanding immune responses' heterogeneity within the TME and identifying biomarkers predicting outcomes.

In cancer, glycoimmunology explores glycosylation pattern alterations contributing to immune escape, a treatment challenge. The host glycosylation machinery shapes responses and influences diseases like HIV, providing therapeutic insights [36]. Understanding these processes is crucial for developing strategies counteracting tumors' evasion.

Glycoimmunology enhances understanding of immune regulation in cancer and highlights glycan-targeted therapies' potential. By clarifying glycans' roles in modulation and elucidating interactions with glycan-binding proteins, this field is set to revolutionize strategies. These advancements hold potential to enhance treatment efficacy and expand immunotherapy, addressing mechanisms of evasion and dysregulated glycosylation in diseases like autoimmunity and cancer. Recent innovations highlight glycans' impact on responses and pathology, opening new drug development avenues [17, 3, 36, 6].

3 Role of Sialyl Glycans and Siglecs in the Tumor Microenvironment

The tumor microenvironment (TME) plays a crucial role in tumor progression and therapeutic resistance. Within this milieu, interactions between sialyl glycans and Siglecs are pivotal in facilitating immune evasion. These interactions are fundamental to understanding immune modulation and tumor progression, offering insights into cancer immunotherapy and novel therapeutic strategies.

3.1 Significance of Interactions in Immune Escape

Sialyl glycans and Siglecs interactions are central to immune escape in the TME, undermining cancer immunotherapies. Siglecs, as sialic acid-binding receptors, recognize sialylated glycans on tumor cells, aiding immune evasion by suppressing immune activation and fostering an immunosuppressive environment [1]. Structural features like the extended form of sialoadhesin (Sn) allow Siglecs to bypass inhibitory cis-interactions, engaging in trans interactions that modulate immune responses [37]. These interactions influence immune cell infiltration and activation patterns within the tumor immune microenvironment (TIME), contributing to immune escape [38].

The development of Siglec-Fc constructs, optimized for selective glycan ligand binding, represents a promising strategy to counteract immune escape mechanisms [8]. Enhancing the specificity and affinity of these constructs may effectively modulate immune responses and target sialyl glycan-Siglec interactions.

3.2 Siglec Signaling and Immune Modulation

Siglecs, sialic acid-binding lectins, modulate immune responses by binding sialylated glycans, influencing immune tolerance, inflammation resolution, and acquired immune responses [16, 12, 11]. These interactions regulate immune cell behavior, impacting both innate and adaptive responses. Engineered Siglec-Fc proteins have facilitated detailed profiling of Siglec-ligand interactions, revealing their roles in immune regulation [8].

Siglec-G, notably, exerts negative regulatory effects on inflammation, particularly in B-1a and myeloid cells, maintaining immune homeostasis [19]. Variability in sulfation patterns significantly influences Siglec binding, presenting opportunities for immune response modulation [39]. The structural uniqueness of sialoadhesin (Sn) facilitates trans interactions, contrasting with other Siglecs inhibited by cis-interactions [37]. Recent studies suggest Siglec-E's role in macrophages requires further investigation [14].

The intricate signaling pathways activated by Siglecs, such as Siglec-G and Siglec-E, are essential in balancing immune activation and suppression. Siglec-G regulates B-cell receptor signaling, maintaining homeostasis, while Siglec-E acts as a Toll-like receptor signaling regulator, though its role in cytokine production remains unclear [13, 19, 14]. Understanding these pathways is crucial for developing targeted therapies to modulate immune functions in diseases like cancer.

3.3 Influence of Genetic Variability and Glycosylation Patterns

Genetic variability and glycosylation patterns critically impact sialyl glycan-Siglec interactions, influencing immune modulation and cancer progression. The structural diversity of sialyl glycans, regulated by genetic factors, dictates glycosyltransferase and sialyltransferase activity, affecting functional specificity [5]. Advances in fractionation and derivatization techniques have elucidated the structural complexity of sialyl glycans [5].

Genetic differences can alter glycosylation patterns, impacting the TME's immune landscape and immunotherapy efficacy [33]. Protein-protein interaction analyses provide insights into the conservation and functionality of Siglec-related pathways, crucial for understanding immune modulation and cancer progression [40].

The relationship between genetic variability and glycosylation significantly influences sialyl glycan-Siglec interactions, essential for immune responses and cancer progression. Advances in glycobiology have highlighted how sialylation modulates these interactions, emphasizing the importance of genetic and enzymatic processes in shaping the immune landscape and therapeutic outcomes [3, 2]. Understanding these influences is vital for developing targeted therapeutic strategies to enhance cancer treatment outcomes.

4 Challenges in Cancer Immunotherapy

Cancer immunotherapy faces substantial challenges due to the complex interplay between the tumor microenvironment (TME) and immune response mechanisms, particularly concerning immune checkpoint inhibitors (ICIs). As illustrated in Figure 2, the hierarchical challenges in cancer immunotherapy are highlighted, showcasing the limitations of current ICIs alongside the complexities associated with glycan profiling and detection. This figure further delineates the mechanisms of immune escape and resistance, categorizing specific challenges that underscore the intricate dynamics between the TME, sialyl glycans, Siglecs, and immune responses. This section delves into the limitations of ICIs, emphasizing how these multifaceted interactions impede therapeutic effectiveness. Addressing these limitations is crucial for paving new research pathways to improve immunotherapy outcomes.



Figure 2: This figure illustrates the hierarchical challenges in cancer immunotherapy, highlighting the limitations of current immune checkpoint inhibitors, the complexities in glycan profiling and detection, and the mechanisms of immune escape and resistance. Each primary category is further divided into specific challenges, emphasizing the intricate interplay between the tumor microenvironment, sialyl glycans, Siglecs, and immune responses.

4.1 Limitations of Current Immune Checkpoint Inhibitors

The efficacy of immune checkpoint inhibitors (ICIs) is significantly constrained by the suppressive nature of the TME and the complexity of immune interactions. The TME suppresses tumor-specific T cells through mechanisms involving stromal and immune cells, hindering effective immune responses [41]. Tumor plasticity and heterogeneity further complicate therapeutic target identification, necessitating a deeper understanding of tumor biology [30]. The interactions between sialyl glycans and Siglecs, involving complex glycosylation pathways, require further exploration to understand their implications in immune contexts [17]. Aberrant glycosylation patterns in tumors influence immune evasion and response, suggesting that targeting these pathways could enhance immunotherapy efficacy [29]. However, the complexity of these pathways poses challenges for effective therapeutic strategies.

Additionally, issues in tumor classification, optimal scheduling, and designing combination therapies hinder treatment predictability [42]. These challenges are compounded by the need to manage unique ICI adverse effects, necessitating new evaluation criteria for treatment efficacy [43]. Traditional methods inadequately target the TME without harming healthy tissues, highlighting the potential for strategies that enhance treatment efficacy by focusing on the TME [44]. Developing ICIs capable of navigating the complex immune landscape and overcoming TME suppressive effects is essential for improving therapeutic outcomes.

4.2 Challenges in Glycan Profiling and Detection

Benchmark	Size	Domain	Task Format	Metric

Table 1: This table provides an overview of representative benchmarks used in glycan profiling and detection studies. It details the size, domain, task format, and metric associated with each benchmark, offering insights into the current methodologies and their applicability in the context of tumor microenvironment (TME) analysis.

Glycan profiling and detection within the TME face significant challenges due to the complexity and heterogeneity of glycan structures. Current methods often struggle with positional isomer discrimination, a critical limitation given glycans' structural diversity [5]. Derivatization processes intended to enhance detection can complicate data analysis. Multivalent presentations and Fc receptor interactions in glycan detection can lead to off-target binding and reduced accuracy [8]. The need for precise targeting strategies to ensure effective systemic delivery of immunotherapeutics without toxicity remains unresolved [45]. In head and neck cancer (HNC), the complexity of immune interactions within the TME complicates glycan profiling efforts, with existing immunotherapies benefiting only a small percentage of patients [46]. The lack of accessible experimental tools for non-experts restricts the widespread adoption of advanced glycan analysis techniques, limiting exploration of glycan-mediated immune modulation [3]. Table 1 highlights the representative benchmarks that are crucial for addressing the challenges in glycan profiling and detection within the tumor microenvironment. Developing user-friendly tools and methodologies is crucial for overcoming these barriers and advancing our understanding of glycan roles in cancer progression and immune evasion.

4.3 Mechanisms of Immune Escape and Resistance

Tumor immune evasion and resistance mechanisms are multifaceted, with sialyl glycans and Siglecs playing critical roles. Sialyl glycans, with terminal sialic acid residues, mimic host cell structures, hindering immune recognition. This mimicry is complicated by the structural diversity of sialyl linkage isomers, challenging accurate detection [47]. Siglecs, as sialic acid-binding receptors, are integral to evasion strategies, modulating immune responses through interactions with sialylated ligands on tumor cells [39]. Such interactions inhibit immune cell activation, fostering an immunosuppressive environment that allows tumors to evade surveillance. The tumor immune microenvironment (TIME) exhibits distinct phenotypes, each with unique immune escape strategies contributing to resistance against immunotherapy [38]. Variability in PD-L1 expression among tumors and patients, coupled with complex TME interactions, complicates understanding immune suppression mechanisms [24]. Host genetic variability influences infection outcomes and immune responses, but is less documented than viral genetic variability, complicating the identification of genetic factors affecting tumor behavior and treatment resistance [10]. Siglec-15 exemplifies the challenges in understanding Siglec signaling pathways and interactions, particularly in identifying ligands and biological contexts [15]. The regulatory mechanisms in Siglec-ganglioside interactions complicate efforts to establish their biological significance [16]. The heterogeneous nature of macrophages and their phenotype-switching ability can lead to inconsistent therapeutic responses, emphasizing the need for more targeted immunotherapy approaches [23]. Spatial variability among tumor regions further complicates analysis of their effects on immune cells, presenting obstacles to understanding immune escape mechanisms [25]. Focusing on a limited number of species in studies of Siglec-1 functions may not encompass its full diversity across mammals, limiting generalizability [40]. Current research also lacks comprehensive understanding of how glycomic alterations influence HIV persistence and immune responses, which could provide insights into similar processes in cancer [36].

5 Advancements in Glycoimmunology

Category	Feature	Method
Innovative Therapeutic Strategies	Hypothetical Scenario Exploration Immune System Enhancement	COF[20] ISF[25]
Personalized Medicine and Biomarker Development	Immunotherapy Prediction	TI[38]
Advancements in Glycan Analysis	Glycan Structural Analysis	SALSA-Fractionation[5]

Table 2: This table provides a comprehensive overview of the latest methods employed in the field of glycoimmunology, highlighting innovative therapeutic strategies, personalized medicine and biomarker development, and advancements in glycan analysis. Each method is categorized based on its application in exploring hypothetical scenarios, enhancing immune systems, predicting immunotherapy outcomes, and analyzing glycan structures, demonstrating the integration of novel technologies to improve cancer treatment outcomes.

The field of glycoimmunology explores the complex interactions between glycans and immune responses, particularly in cancer. Understanding these interactions reveals mechanisms of immune modulation and identifies therapeutic targets to enhance cancer treatment outcomes. This section focuses on targeting Siglecs—sialic acid-binding immunoglobulin-like lectins—within the tumor microenvironment (TME) to develop innovative strategies in glycoimmunology that could significantly impact cancer therapy. Table 2 presents a detailed summary of the methods used in advancing glycoimmunology, focusing on innovative therapeutic strategies, personalized medicine, and glycan analysis, which are crucial for developing effective cancer therapies. Additionally, Table 3 offers a comprehensive comparison of the key methods employed in advancing glycoimmunology, emphasizing their distinct therapeutic focuses, technological integrations, and research directions relevant to cancer therapy.

5.1 Therapeutic Targeting of Siglecs

Targeting Siglecs can improve cancer treatment by modulating TME immune responses. Siglecs facilitate immune evasion and tumor progression through interactions with sialylated glycans on tumor cells [15]. Disrupting these interactions may counteract immunosuppressive signals, enhancing anti-tumor immunity. Siglec-15, a notable therapeutic target, modulates tumor immune responses [15]. Targeting Siglec-15 can enhance antitumor immunity by disrupting interactions with sialylated ligands, promoting immune cell activation. Additionally, Siglec-ganglioside interactions offer therapeutic opportunities, influencing immune and nervous system responses [16].

Nanomedicine enhances immunotherapeutic delivery through targeted systems [41]. Utilizing Siglec-ligand specificity, nanotechnology enables precise therapeutic delivery to the TME, improving antitumor effects while minimizing toxicity. Glycoengineering allows monoclonal antibodies with tailored glycosylation profiles [17]. Engineered antibodies targeting specific Siglecs can enhance binding affinity and therapeutic efficacy. Mathematical modeling optimizes therapeutic strategies, addressing challenges in tumor classification, treatment scheduling, and combination therapy design [42]. These models elucidate tumor-immune interaction dynamics, informing effective regimens.

Future research should explore combination therapies, improve patient selection based on biomarkers, and refine evaluation metrics for immune checkpoint inhibitors (ICIs) [43]. Understanding tumor microenvironments and identifying biomarkers for patient selection can guide combination therapy development [32]. The role of Siglec-E in TLR4 signaling provides insights for therapeutic targeting [14].

Siglec targeting, particularly with recombinant Siglec-Fc fusion proteins, shows promise for enhancing cancer treatment. These proteins effectively detect cancer cell ligands and improve strategies by addressing dysregulated glycosylation linked to tumor progression and immune evasion [18, 6]. Leveraging Siglec-ligand specificity and integrating nanomedicine and glycoengineering insights can bolster antitumor immunity and tackle TME challenges.

5.2 Innovative Therapeutic Strategies

Innovative cancer therapies emphasize combination strategies and immune modulation to enhance existing treatments like ICIs. These approaches aim to overcome TME limitations and improve

outcomes by addressing multidrug resistance and other cancer therapy challenges [35]. Combination therapies targeting multiple pathways can enhance ICI effectiveness. By combining ICIs with agents targeting metabolic pathways, immune cell functionality is preserved while disrupting tumor metabolic adaptations [21]. This approach enhances immune response and mitigates resistance by attacking cancer cells from various angles.

Advanced technologies, such as convolutional neural networks trained on imaging mass cytometry data, offer insights into T-cell presence within tumors. These technologies enable tumor perturbation design through counterfactual optimization, predicting and enhancing immune responses [20]. Understanding immune cell spatial distribution and interactions with tumor regions allows for calculating influence scores, reflecting specific tumor areas' impact on immune behavior [25]. This information is crucial for developing targeted therapies that modulate the TME to favor immune activation.

Future research should explore combination therapies incorporating TME-targeted strategies to enhance ICI efficacy and reduce multidrug resistance [35]. Targeting immune checkpoints and TME components could synergistically enhance antitumor immunity and improve outcomes. Developing biomarkers to guide patient selection and treatment personalization is essential for maximizing these approaches' benefits [34].

Investigating innovative therapeutic approaches combining modalities like immunotherapy and nanomedicine holds potential for enhancing cancer treatment. This includes leveraging combination therapies addressing TME complexities and utilizing immune modulation to activate the body's immune response against tumors. Incorporating advanced strategies, including mathematical modeling for treatment design optimization and nanomedicine for improved immunomodulator delivery, aims to increase existing therapies' efficacy and reduce toxicities, broadening patient benefit [42, 31, 35, 44, 45]. Addressing TME complexities and leveraging cutting-edge technologies aim to enhance current therapies' effectiveness and provide new cancer combat avenues.

5.3 Nanomedicine and Drug Delivery

Nanomedicine transforms targeted TME therapy delivery, enhancing cancer treatment efficacy while minimizing off-target effects. Integrating nanotechnology into drug delivery systems enables precise tumor cell targeting, improving anticancer agents' pharmacokinetics and therapeutic index [45]. Leveraging nanoparticles' unique properties—size, surface charge, and functionalization capabilities—researchers design delivery vehicles that overcome biological barriers and selectively accumulate in tumor tissues.

Developing targeted delivery systems is crucial for enhancing immunotherapy action, as these systems can deliver therapeutic agents directly to the TME. This targeted approach maximizes drug concentration at the tumor site while reducing systemic exposure and toxicities. Nanoparticles functionalized with ligands recognizing specific tumor antigens or receptors ensure precise and effective immunotherapeutic delivery [45].

Nanomedicine applications extend to improving therapeutics' pharmacokinetics, allowing controlled release and prolonged circulation times. These advancements maintain therapeutic efficacy and reduce dosing frequency, enhancing patient compliance and outcomes [45]. Modulating drug release profiles through nanocarriers offers a strategic advantage in cancer management, where sustained drug exposure is necessary for optimal effects.

Future nanomedicine research should focus on developing multi-scale models integrating cellular and molecular dynamics to understand nanoparticle interactions with the biological environment [42]. Such models provide insights into nanomedicine-enhanced immunotherapies' mechanisms and inform new therapeutic approaches that minimize toxicity while maximizing efficacy. Exploring nanomedicine's potential in combination with other modalities can pave the way for novel strategies addressing TME complexities and improving cancer outcomes.

5.4 Personalized Medicine and Biomarker Development

Integrating personalized medicine and biomarker development in glycoimmunology promises advanced cancer treatment by tailoring therapies to individual profiles. The tumor immune microenvironment (TIME) index serves as a prognostic and immunotherapeutic signature, guiding personalized

strategies in glycoimmunology [38]. Utilizing the TIME index enables better prediction of patient responses to immunotherapies, optimizing therapeutic outcomes.

Comprehensive TME cell infiltration pattern analysis, such as in colorectal cancer (CRC), underscores the importance of immune cell infiltration and cancer prognosis relationships [48]. These insights inform personalized strategies accounting for each patient's unique immune landscape, enhancing immunotherapy effectiveness.

In head and neck cancer (HNC), diverse immune escape mechanisms inform more effective immunotherapy development by targeting specific pathways [46]. Identifying and targeting immune escape strategies employed by different tumor types can improve cancer treatment precision and efficacy.

Future research should focus on developing biomarker-guided therapies and combinatory approaches integrating TME-targeting strategies with traditional treatments [22]. Incorporating biomarkers reflecting dynamic TME interactions enhances cancer therapies' precision and outcomes.

Optimizing nanomaterial formulations for specific cancer types and exploring combination therapies can further enhance personalized medicine's potential in glycoimmunology [41]. Understanding nanomaterials' immune system interactions is crucial for maximizing therapeutic benefits and minimizing adverse effects, paving the way for more effective individualized treatments.

Developing personalized medicine and biomarker-guided therapies in glycoimmunology represents a shift towards more targeted and effective cancer treatments. Customizing therapies to individual tumors' biological characteristics and surrounding immune microenvironments can enhance efficacy, address tumor heterogeneity complexities, and advance cancer immunotherapy. This approach considers TME immunosuppressive nature and tumor-immune component interactions, leading to more effective personalized interventions [42, 20, 35, 44, 25].

5.5 Advancements in Glycan Analysis

Technological advancements in glycan analysis have enhanced complex glycan structure characterization, providing insights into their biological roles and cancer implications. Novel methods reduce sample complexity and improve structural characterization. For instance, a recent approach identified 52 sialylated N-glycan structures, including 107 linkage isomers, enhancing structural characterization in complex samples [5]. This method enables a detailed understanding of glycan structural diversity, crucial for elucidating functional roles in immune modulation and cancer progression.

Another advancement is electron-transfer/higher-energy collision dissociation (EThcD), providing comprehensive glycan and peptide structure information. This technique enhances complex glycopeptide characterization, facilitating a deeper understanding of glycan-protein interactions and implications for immune responses and disease mechanisms [7]. Accurately characterizing glycopeptides is important in cancer, where glycosylation pattern alterations influence tumor behavior and immune evasion.

These glycan analysis advancements have profound research implications, enabling novel biomarker and therapeutic target identification. By understanding glycan structures and protein interactions, researchers uncover complex immune modulation and tumor progression mechanisms, particularly how specific glycoconjugates, like sialylated N-glycans, influence immune responses and cancer dynamics through cell surface recognition and signaling pathways. This insight is critical for advancing therapeutic strategies in cancer immunotherapy and addressing tumor immune evasion challenges [29, 3, 2]. As glycan analysis techniques evolve, they will contribute to glycoimmunology advancement and cancer research application.

6 Conclusion

The exploration of sialyl glycans and Siglecs within the tumor microenvironment (TME) underscores their pivotal roles in modulating immune responses and facilitating cancer progression. These interactions are instrumental in understanding immune evasion and resistance mechanisms, which are major hurdles in cancer immunotherapy. Advances in glycan analysis, such as those utilizing EThcD for detailed structural elucidation of mucin-type O-glycans, have significantly contributed to

Feature	Therapeutic Targeting of Siglecs	Innovative Therapeutic Strategies	Nanomedicine and Drug Delivery
Therapeutic Focus	Siglec Modulation	Immune Modulation	Targeted Delivery
Technological Integration	Nanomedicine	Advanced Technologies	Nanotechnology
Research Direction	Combination Therapies	Combination Therapies	Multi-scale Modeling

Table 3: This table provides a comparative analysis of three major approaches in glycoimmunology: therapeutic targeting of Siglecs, innovative therapeutic strategies, and nanomedicine and drug delivery. It highlights the therapeutic focus, technological integration, and research direction for each approach, illustrating their roles in advancing cancer treatment through immune modulation and targeted delivery.

our comprehension of glycans' biological functions, thereby informing the development of targeted therapeutic interventions.

The dual function of Siglec-15 in inhibiting T cell activity highlights the need for in-depth research to unravel its mechanisms and develop strategies to modulate its effects, enhancing antitumor immunity. A thorough grasp of glycan-immune interactions is crucial for progressing next-generation immunotherapies, as recent studies emphasize the need for refined experimental models and the identification of key glycoconjugates as viable therapeutic targets.

The integration of personalized medicine, supported by technologies like label-free Raman spectroscopy, offers promising avenues for tailoring cancer treatments to individual patient profiles, particularly for those with microsatellite instability-high (MSI-H) tumors. Moreover, the advancing field of nanomedicine is improving the safety and effectiveness of immunotherapies, as demonstrated by promising outcomes in ongoing clinical trials. Additionally, the impact of host genetic variability on individual responses to cancer therapies highlights the necessity of incorporating genetic considerations into treatment planning.

References

[1] Eline JH van Houtum, Christian Büll, Lenneke AM Cornelissen, and Gosse J Adema. Siglec signaling in the tumor microenvironment. *Frontiers in immunology*, 12:790317, 2021.

[2] Gaurang P Bhide and Karen J Colley. Sialylation of n-glycans: mechanism, cellular compartmentalization and function. *Histochemistry and cell biology*, 147:149–174, 2017.

[3] Douglas M Oswald and Brian A Cobb. Emerging glycobiology tools: a renaissance in accessibility. *Cellular immunology*, 333:2–8, 2018.

[4] Andreia Peixoto, Andreia Miranda, Lúcio Lara Santos, and José Alexandre Ferreira. A roadmap for translational cancer glycoimmunology at single cell resolution. *Journal of Experimental & Clinical Cancer Research*, 41(1):143, 2022.

[5] Xiaomei Zhou, Woran Song, Milos V Novotny, and Stephen C Jacobson. Fractionation and characterization of sialyl linkage isomers of serum n-glycans by ce–ms. *Journal of separation science*, 45(17):3348–3361, 2022.

[6] Benjamin AH Smith and Carolyn R Bertozzi. The clinical impact of glycobiology: targeting selectins, siglecs and mammalian glycans. *Nature Reviews Drug Discovery*, 20(3):217–243, 2021.

[7] Zsuzsanna Darula, Ádám Pap, and Katalin F Medzihradszky. Extended sialylated o-glycan repertoire of human urinary glycoproteins discovered and characterized using electron-transfer/higher-energy collision dissociation. *Journal of Proteome Research*, 18(1):280–291, 2018.

[8] Emily Rodrigues, Jaesoo Jung, Heajin Park, Caleb Loo, Sepideh Soukhtehzari, Elena N Kitova, Fahima Mozaneh, Gour Daskhan, Edward N Schmidt, Vivian Aghanya, et al. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands. *Nature communications*, 11(1):5091, 2020.

[9] Nongluk Sriwilaijaroen and Yasuo Suzuki. Sialoglycovirology of lectins: sialyl glycan binding of enveloped and non-enveloped viruses. *Lectin Purification and Analysis: Methods and Protocols*, pages 483–545, 2020.

[10] Ana Carolina Arcanjo, Giovanni Mazzocco, Silviene Fabiana de Oliveira, Dariusz Plewczynski, and Jan P. Radomski. Role of the host genetic variability in the influenza-a virus susceptibility; a review, 2014.

[11] Jeremy A O'Sullivan, Daniela J Carroll, and Bruce S Bochner. Glycobiology of eosinophilic inflammation: contributions of siglecs, glycans, and other glycan-binding proteins. *Frontiers in Medicine*, 4:116, 2017.

[12] Joyce Lübbers, Ernesto Rodríguez, and Yvette Van Kooyk. Modulation of immune tolerance via siglec-sialic acid interactions. *Frontiers in immunology*, 9:2807, 2018.

[13] Sarah J Meyer, Alexandra T Linder, Carolin Brandl, and Lars Nitschke. B cell siglecs–news on signaling and its interplay with ligand binding. *Frontiers in immunology*, 9:2820, 2018.

[14] Manjula Nagala, Emma McKenzie, Hannah Richards, Ritu Sharma, Sarah Thomson, Pietro Mastroeni, and Paul R Crocker. Expression of siglec-e alters the proteome of lipopolysaccharide (lps)-activated macrophages but does not affect lps-driven cytokine production or toll-like receptor 4 endocytosis. *Frontiers in Immunology*, 8:1926, 2018.

[15] Takashi Angata. Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases. *Journal of biomedical science*, 27(1):10, 2020.

[16] Ronald L Schnaar. Gangliosides as siglec ligands. *Glycoconjugate journal*, 40(2):159–167, 2023.

[17] Sara Trzos, Paweł Link-Lenczowski, and Ewa Pocheć. The role of n-glycosylation in b-cell biology and igg activity. the aspects of autoimmunity and anti-inflammatory therapy. *Frontiers in Immunology*, 14:1188838, 2023.

[18] Kaijun Chi, Huilin Xu, Hanjie Li, Ganglong Yang, Xiaoman Zhou, and Xiao-Dong Gao. Expression of a siglec-fc protein and its characterization. *Biology*, 12(4):574, 2023.

[19] William Royster, Ping Wang, and Monowar Aziz. The role of siglec-g on immune cells in sepsis. *Frontiers in Immunology*, 12:621627, 2021.

[20] Zitong Jerry Wang, Alexander M. Xu, Aman Bhargava, and Matt W. Thomson. Generating counterfactual explanations of tumor spatial proteomes to discover effective strategies for enhancing immune infiltration, 2023.

[21] Kathrin Renner, Katrin Singer, Gudrun E Koehl, Edward K Geissler, Katrin Peter, Peter J Siska, and Marina Kreutz. Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. *Frontiers in immunology*, 8:248, 2017.

[22] Yi Xiao and Dihua Yu. Tumor microenvironment as a therapeutic target in cancer. *Pharmacology & therapeutics*, 221:107753, 2021.

[23] Zhaojun Duan and Yunping Luo. Targeting macrophages in cancer immunotherapy. *Signal transduction and targeted therapy*, 6(1):127, 2021.

[24] Xianjie Jiang, Jie Wang, Xiangying Deng, Fang Xiong, Junshang Ge, Bo Xiang, Xu Wu, Jian Ma, Ming Zhou, Xiaoling Li, et al. Role of the tumor microenvironment in pd-l1/pd-1-mediated tumor immune escape. *Molecular cancer*, 18:1–17, 2019.

[25] Mahmudul Hasan, Jakub R. Kaczmarzyk, David Paredes, Lyanne Oblein, Jaymie Oentoro, Shahira Abousamra, Michael Horowitz, Dimitris Samaras, Chao Chen, Tahsin Kurc, Kenneth R. Shroyer, and Joel Saltz. A novel framework for characterization of tumor-immune spatial relationships in tumor microenvironment, 2022.

[26] Bernadette J. Stolz, Jagdeep Dhesi, Joshua A. Bull, Heather A. Harrington, Helen M. Byrne, and Iris H. R. Yoon. Relational persistent homology for multispecies data with application to the tumor microenvironment, 2023.

[27] Borros Arneth. Tumor microenvironment. *Medicina*, 56(1):15, 2019.

[28] Luca Vago, Ivana Gojo, et al. Immune escape and immunotherapy of acute myeloid leukemia. *The Journal of clinical investigation*, 130(4):1552–1564, 2020.

[29] Jhenifer Santos Dos Reis, Israel Diniz-Lima, Marcos André Rodrigues da Costa Santos, Pedro Marçal Barcelos, Kelli Monteiro da Costa, Raphael do Carmo Valente, Lorrane de Souza Chaves, Luma Petel de Campos, Ariely Costa Dos Santos, Rafaela Gomes Correia de Lima, et al. The blessed union of glycobiology and immunology: a marriage that worked. *Medicines*, 10(2):15, 2023.

[30] Zineb Kaid, Camille Pouchol, and Jean Clairambault. A phenotype-structured model for the tumour-immune response, 2023.

[31] Samantha Burugu, Amanda R Dancsok, and Torsten O Nielsen. Emerging targets in cancer immunotherapy. In *Seminars in cancer biology*, volume 52, pages 39–52. Elsevier, 2018.

[32] Nor Adzimah Johdi and Nur Fazilah Sukor. Colorectal cancer immunotherapy: options and strategies. *Frontiers in immunology*, 11:1624, 2020.

[33] Santosh Kumar Paidi, Joel Rodriguez Troncoso, Piyush Raj, Paola Monterroso Diaz, David E. Lee, Narasimhan Rajaram, and Ishan Barman. Label-free raman spectroscopy and machine learning enables sensitive evaluation of differential response to immunotherapy, 2020.

[34] Salman M Toor, Varun Sasidharan Nair, Julie Decock, and Eyad Elkord. Immune checkpoints in the tumor microenvironment. In *Seminars in cancer biology*, volume 65, pages 1–12. Elsevier, 2020.

[35] Catarina Roma-Rodrigues, Rita Mendes, Pedro V Baptista, and Alexandra R Fernandes. Targeting tumor microenvironment for cancer therapy. *International journal of molecular sciences*, 20(4):840, 2019.

[36] Florent Colomb, Leila B Giron, Irena Trbojevic-Akmacic, Gordan Lauc, and Mohamed Abdel-Mohsen. Breaking the glyco-code of hiv persistence and immunopathogenesis. *Current HIV/AIDS Reports*, 16:151–168, 2019.

[37] Mariliis Klaas, Stuart Dubock, David JP Ferguson, and Paul R Crocker. Sialoadhesin (cd169/siglec-1) is an extended molecule that escapes inhibitory cis-interactions and synergizes with other macrophage receptors to promote phagocytosis. *Glycoconjugate Journal*, 40(2):213–223, 2023.

[38] Zaoqu Liu, Yuyuan Zhang, Chengcheng Shi, Xueliang Zhou, Kaihao Xu, Dechao Jiao, Zhenqiang Sun, and Xinwei Han. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma. *Journal of Translational Medicine*, 19:1–17, 2021.

[39] Jaesoo Jung, Jhon R Enterina, Duong T Bui, Fahima Mozaneh, Po-Han Lin, Nitin, Chu-Wei Kuo, Emily Rodrigues, Abhishek Bhattacherjee, Parisa Raeisimakiani, et al. Carbohydrate sulfation as a mechanism for fine-tuning siglec ligands. *ACS Chemical Biology*, 16(11):2673–2689, 2021.

[40] Hazem Almhanna, Arun HS Kumar, David Kilroy, Gina Duggan, Jane A Irwin, Bridget Hogg, and Colm Reid. Comparison of siglec-1 protein networks and expression patterns in sperm and male reproductive tracts of mice, rats, and humans. *Veterinary World*, 17(3):645, 2024.

[41] Wantong Song, Sara N Musetti, and Leaf Huang. Nanomaterials for cancer immunotherapy. *Biomaterials*, 148:16–30, 2017.

[42] Anna Konstorum, Anthony T. Vella, Adam J. Adler, and Reinhard Laubenbacher. Addressing current challenges in cancer immunotherapy with mathematical and computational modeling, 2017.

[43] Caroline Robert. A decade of immune-checkpoint inhibitors in cancer therapy. *Nature communications*, 11(1):3801, 2020.

[44] J-J Wang, K-F Lei, and FJERMPS Han. Tumor microenvironment: recent advances in various cancer treatments. *European Review for Medical & Pharmacological Sciences*, 22(12), 2018.

[45] Darrell J Irvine and Eric L Dane. Enhancing cancer immunotherapy with nanomedicine. *Nature Reviews Immunology*, 20(5):321–334, 2020.

[46] Kourtney L Kostecki, Mari Iida, Bridget E Crossman, Ravi Salgia, Paul M Harari, Justine Y Bruce, and Deric L Wheeler. Immune escape strategies in head and neck cancer: Evade, resist, inhibit, recruit. *Cancers*, 16(2):312, 2024.

[47] Juliane Mayr, Kam Lau, Jimmy CC Lai, Ivan A Gagarinov, Yun Shi, Sarah McAtamney, Renee WY Chan, John Nicholls, Mark von Itzstein, and Thomas Haselhorst. Unravelling the role of o-glycans in influenza a virus infection. *Scientific reports*, 8(1):16382, 2018.

[48] Yihao Mao, Yuqiu Xu, Jiang Chang, Wenju Chang, Yang Lv, Peng Zheng, Zhiyuan Zhang, Zhiqiang Li, Qi Lin, Wentao Tang, et al. The immune phenotypes and different immune escape mechanisms in colorectal cancer. *Frontiers in Immunology*, 13:968089, 2022.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.